Clinical trials
Psychosis clinical trials
Below are recruiting psychosis clinical trials, each written for real people, not researchers. We’re tracking 146 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04789915RecruitingPhase 1
Testing memantine added to dopamine-targeting treatment for early psychosis
This Phase 1 study tests whether adding memantine can improve “negative symptoms” (like low motivation, reduced emotional expression) in people having their first episode of psychosis. It’s designed to understand safety and early effects when dopamine-related treatment is adjusted.
Glostrup Municipality, Capitol RegionAges 18–45 - NCT07459257Recruiting
Predicting psychiatric symptoms in methamphetamine psychosis
This study looks for patterns in psychiatric symptoms among people who have psychotic symptoms caused by methamphetamine use. You may qualify if you are 18-65, haven't taken psychiatric medication for at least a month, and do not have certain other health conditions.
Elâzığ, ElâzığAges 18–65 - NCT07459270Recruiting
Psychotic symptoms in methamphetamine users with and without cannabis
This study compares people who have psychosis from methamphetamine and also use cannabis with those who only have methamphetamine-induced psychosis. It aims to understand how cannabis may affect their symptoms.
Elâzığ, ElâzığAges 18–65 - NCT07459660Enrolling by invitationPhase 2
Long-term study of ML-007C-MA for Alzheimer's psychosis
This trial tests a long-term treatment (ML-007C-MA) for people with Alzheimer's disease who have psychosis. It is for those who already completed an earlier study with the same drug and may benefit from continuing it. The goal is to see if ongoing treatment is helpful and safe.
Anaheim, CaliforniaAges 55–91 - NCT07417904Recruiting
Brave program for safety and violence risk in early psychosis
This trial tests a program called BRAVE to help young people with early psychosis learn skills to stay safe and reduce violence risk. It is for those already getting care at a clinic and considered stable enough to participate.
Washington D.C., District of ColumbiaAges 16–30 - NCT07408934Enrolling by invitation
Group therapy for feeling safer with psychosis
This trial tests a group therapy program called the Feeling Safe Programme for people with psychosis. It aims to help you learn new ways to cope with your symptoms and feel safer. It meets once a week for 75 minutes.
Ottawa, OntarioAges 18 years+ - NCT05763966Recruiting
Uppsala study of psychosis risk and early psychosis
This study follows people with early psychosis, or a high risk of developing psychosis, to better understand brain and symptom changes over time. It may help future prevention or treatment by comparing brain/clinical measurements between people who are at risk, recently affected, and healthy controls.
UppsalaAges 18–40 - NCT07360665Recruiting
Exercise program for people with psychosis on injectable meds
This trial tests a personalized exercise program for people with psychosis who take long-acting injectable antipsychotics. The goal is to see if regular physical activity can improve overall health and well-being.
Vila RealAges 18 years+ - NCT06728241Recruiting
Virtual reality and AI therapy for psychosis
This study tests if virtual reality and artificial intelligence can help people with psychosis overcome difficulties going outside or doing everyday activities. It uses VR scenarios and AI tools to support treatment.
Oslo, NorwayAges 17–65 - NCT07225179Recruiting
Mobile help for caregivers of young adults with early psychosis
This study tests a mobile app (Bolster) designed to support caregivers of young adults who have recently experienced psychosis. It aims to provide resources and connections to help you care for your loved one and yourself.
Chapel Hill, North CarolinaAges 18 years+ - NCT07226895RecruitingPhase 1/Phase 2
Study of MT1988 for people at high risk for psychosis
This trial tests a new drug called MT1988 in people who show early warning signs of psychosis. Researchers want to see if it changes certain markers in the body related to mental health.
Irvine, CaliforniaAges 17–30 - NCT06542640Recruiting
Understanding brain changes in youth at risk for psychosis
This research study looks at how the brain changes in young people who are at high risk for developing psychosis. It aims to find better ways to predict and prevent psychosis by using brain imaging and thinking tests.
Shanghai, Shanghai MunicipalityAges 15–35 - NCT07146802Recruiting
Personalized thinking training for psychosis
This trial tests a personalized thinking training program for people with schizophrenia to help reduce symptoms like delusions or suspiciousness. It might be a good fit if you have had some of these symptoms recently and are stable on your current treatment.
StrasbourgAges 18–65 - NCT07095465RecruitingPhase 3
Long-term study of ACP-204 for psychosis in Lewy body dementia
This study tests a medication called ACP-204 for psychosis (hallucinations or delusions) in people with Lewy body dementia. It is a long-term extension open to patients who completed a previous ACP-204 study, to see if the drug continues to be helpful and safe.
Irvine, CaliforniaAges 55–84 - NCT07093671Recruiting
Therapy for Teens and Young Adults at Risk for Psychosis
This trial tests a type of therapy called Mentalization Based Treatment (MBT) for young people who are at high risk for developing psychosis. The therapy helps you understand your own and others' thoughts and feelings, with the goal of reducing distress and preventing psychosis.
LausanneAges 14–30 - NCT06978803Recruiting
Speech and brain study for early psychosis
This study looks at how people with early psychosis (within the first 5 years of treatment) talk during conversations. Researchers hope to learn more about speech patterns and brain activity related to psychosis.
Montreal, QuebecAges 18–60 - NCT07060742Recruiting
Exergames for older adults with psychosis
This trial tests if playing specially designed video games (called exergames) can help older adults with psychosis improve their physical and mental health. It may be a good fit if you're 55 or older, have a psychotic disorder, and can stand for a few minutes.
Basel, Canton of Basel-CityAges 55 years+ - NCT07056894Recruiting
Cognitive training for substance use in early psychosis
This study tests a computer-based cognitive training program to help people with early psychosis reduce their alcohol and cannabis use. The program is designed to improve thinking skills and may make it easier to cut back on substance use.
St. John's, Newfoundland and LabradorAges 16–30 - NCT07029581RecruitingPhase 2
Testing ACP-204 for psychosis in Lewy body dementia
This trial tests a new drug called ACP-204 for people with dementia from Lewy body disease or Parkinson's who also have hallucinations or delusions. The goal is to see if the drug can safely reduce these symptoms without worsening thinking problems.
Irvine, CaliforniaAges 55–84 - NCT07001878RecruitingPhase 4
Cannabis Strength and Brain Health in Early Psychosis
This trial studies how different strengths of cannabis affect the brain's white matter in people with early psychosis. It may help doctors understand which cannabis potencies are less harmful for young adults with psychosis.
St. John's, Newfoundland and LabradorAges 18–25 - NCT06978881Enrolling by invitation
Brain activity study for stable schizophrenia
This study uses a brain scan called magnetoencephalography (MEG) to understand brain activity in people with schizophrenia. It may help researchers learn more about the condition and could lead to better treatments.
Montreal, QuebecAges 18–50 - NCT06947941RecruitingPhase 3
Testing karxt for psychosis in alzheimer's disease
This study tests whether a new medicine called KarXT can help with psychosis (hallucinations or delusions) in people with Alzheimer's disease. It aims to reduce troubling symptoms while being safe for older adults.
Gilbert, ArizonaAges 55–90 - NCT06928935Recruiting
Digital therapy for teens and young adults at risk for psychosis
This study tests a digital version of dialectical behavioural therapy (a type of talk therapy) to help young people who have early signs of psychosis. It aims to see if this therapy can reduce symptoms and improve well-being.
Toronto, OntarioAges 14–35 - NCT06887192RecruitingPhase 2
Testing ML-007C-MA for Alzheimer's Psychosis
This trial tests a study drug called ML-007C-MA to see if it can safely reduce hallucinations and delusions in people with Alzheimer's disease who also have psychosis. If you or your loved one has Alzheimer's and has been experiencing false beliefs or seeing/hearing things that aren't there for at least two months, this study may be an option.
Phoenix, ArizonaAges 55–90
Hear when a new Psychosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for psychosis?
- Yes. Clin2 currently lists 146 recruiting psychosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a psychosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a psychosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.